Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Biomolecular Screening|January 28, 2009
Characterizing cannabinoid CB2 receptor ligands using DiscoveRx PathHunter beta-arrestin assayDebra McGuinness, Asra Malikzay, Richard Visconti, et al.
The EMBO Journal|May 30, 2003
Alp13, an MRG family protein, is a component of fission yeast Clr6 histone deacetylase required for genomic integrityJun-Ichi Nakayama, Guoping Xiao, Ken-Ichi Noma, et al.
Translational Oncology|October 2, 2010
Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization InhibitorMaria Carolina Tuma, Asra Malikzay, Xiaohu Ouyang, et al.
Journal of Biomolecular Screening|December 19, 2009
Screening for antibacterial inhibitors of the UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) using a high-throughput mass spectrometry assayErik F Langsdorf, Asra Malikzay, William A Lamarr, et al.
NAR Cancer|January 11, 2024
Codelivery of TGFβ and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to Immune Checkpoint InhibitorsWookhyun Kim, Zhou Ye, Vera Simonenko, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2010
Expansion of SAR studies on triaryl bis sulfone cannabinoid CB2 receptor ligandsLing Tong, B B Shankar, Lei Chen, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2017
Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosidesFrank Bennett, Alexei V Buevich, Hsueh-Cheng Huang, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2009
Non-aromatic A-ring replacement in the triaryl bis-sulfone CB2 receptor inhibitorsEric J Gilbert, Guowei Zhou, Michael K C Wong, et al.
Bioorganic & Medicinal Chemistry Letters|December 27, 2005
Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell linesXiaohu Ouyang, Evgueni L Piatnitski, Vatee Pattaropong, et al.
Molecular Cancer Therapeutics|March 16, 2005
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic targetNick Loizos, Yan Xu, Jim Huber, et al.
Pageof 2